Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Association of Patients' Epidemiological Characteristics and Comorbidities with Severity and Related Mortality Risk of SARS-CoV-2 Infection: Results of an Umbrella Systematic Review and Meta-Analysis

  • Reyna-Villasmil, Eduardo
  • Caponcello, Maria Giulia
  • Maldonado, Natalia
  • Olivares Navarro, Paula
  • Caroccia, Natascia
  • Bonazzetti, Cecilia
  • Tazza, Beatrice
  • Carrara, Elena
  • Giannella, Maddalena
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
  • Palacios-Baena, Zaira Raquel
The objective of this study was to assess the association between patients’ epidemiological characteristics and comorbidities with SARS-CoV-2 infection severity and related mortality risk. An umbrella systematic review, including a meta-analysis examining the association between patients’ underlying conditions and severity (defined as need for hospitalization) and mortality of COVID-19, was performed. Studies were included if they reported pooled risk estimates of at least three underlying determinants for hospitalization, critical disease (ICU admission, mechanical ventilation), and hospital mortality in patients diagnosed with SARS-CoV-2 infection. Evidence was summarized as pooled odds ratios (pOR) for disease outcomes with 95% confidence intervals (95% CI). Sixteen systematic reviews investigating the possible associations of comorbidities with severity or death from COVID-19 disease were included. Hospitalization was associated with age > 60 years (pOR 3.50; 95% CI 2.97−4.36), smoking habit (pOR 3.50; 95% CI 2.97−4.36), and chronic pulmonary disease (pOR 2.94; 95% CI 2.14−4.04). Chronic pulmonary disease (pOR 2.82; 95% CI 1.92−4.14), cerebrovascular disease (pOR 2.74; 95% CI 1.59−4.74), and cardiovascular disease (pOR 2.44; 95% CI 1.97−3.01) were likely to be associated with increased risk of critical COVID-19. The highest risk of mortality was associated with cardiovascular disease (pOR 3.59; 95% CI 2.83−4.56), cerebrovascular disease (pOR 3.11; 95% CI 2.35−4.11), and chronic renal disease (pOR 3.02; 95% CI 2.61−3.49). In conclusion, this umbrella systematic review provides a comprehensive summary of meta-analyses examining the impact of patients’ characteristics on COVID-19 outcomes. Elderly patients and those cardiovascular, cerebrovascular, and chronic renal disease should be prioritized for pre-exposure and post-exposure prophylaxis and early treatment., This systematic review was developed as part of the ORCHESTRA project (Connecting European Cohorts to increase common and effective SARS-CoV-2 Response), which was funded by the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement no. 101016167)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis

  • Gatti, Milo
  • Rinaldi, Matteo
  • Bussini, Linda
  • Bonazzetti, Cecilia
  • Pascale, Renato
  • Pasquini, Zeno
  • Faní, Francesca
  • Pinho Guedes, Mariana Nunes
  • Azzini, Anna Maria
  • Carrara, Elena
  • Palacios-Baena, Zaira Raquel
  • Caponcello, Maria Giulia
  • Reyna-Villasmil, Eduardo
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
  • Viale, Pierluigi
  • Giannella, Maddalena
  • ORCHESTRA Study Groupt
The ORCHESTRA study group: Natascia Caroccia, Federica Arbizzani, Maria Eugenia Giacomini, Oana Vatamanu, Elisa Razzaboni, Maria Elena De Rui, Anna Gorska, Natalia Maldonado , Paula Olivares, David Gutiérrez-Campos, Ana Belén Martín-Gutiérrez, Virginia Palomo, Almudena Serna, [Background] A significant increased risk of complications and mortality in immunocompromised patients affected by COVID-19 has been described. However, the impact of COVID-19 in solid organ transplant (SOT) recipients is an issue still under debate, due to conflicting evidence that has emerged from different observational studies., [Objectives] We performed a systematic review with a meta-analysis to assess the clinical outcome in SOT recipients with COVID-19 compared with the general population., [Data sources] PubMed-MEDLINE and Scopus were independently searched until 13 October 2021., [Study eligibility criteria] Prospective or retrospective observational studies comparing clinical outcome in SOT recipients versus general populations affected by COVID-19 were included. The primary endpoint was 30-day mortality., [Participants] Participants were patients with confirmed COVID-19., [Methods] The quality of the included studies was independently assessed with the Risk of Bias in Non-randomized Studies of Interventions tool for observational studies. The meta-analysis was performed by pooling ORs retrieved from studies providing adjustment for confounders using a random-effects model with the inverse variance method. Multiple subgroups and sensitivity analyses were conducted to investigate the source of heterogeneity., [Results] A total of 3501 articles were screened, and 31 observational studies (N = 590 375; 5759 SOT recipients vs. 584 616 general population) were included in the meta-analyses. No difference in 30-day mortality rate was found in the primary analysis, including studies providing adjustment for confounders (N = 17; 3752 SOT recipients vs. 159 745 general population; OR: 1.13; 95% CI, 0.94–1.35; I2 = 33.9%). No evidence of publication bias was reported. A higher risk of intensive care unit admission (OR: 1.56; 95% CI, 1.03–2.63) and occurrence of acute kidney injury (OR: 2.50; 95% CI, 1.81–3.45) was found in SOT recipients., [Conclusions] No increased risk in mortality was found in SOT recipients affected by COVID-19 compared with the general population when adjusted for demographic and clinical features and COVID-19 severity., No conflicts of interest to declare. This systematic review was developed as part of the ORCHESTRA project cohort (Connecting European Cohorts to increase common and effective SARS-CoV-2 Response), receiving funding from the European Union's Horizon 2020 research and innovation program (Grant no. 101016167)., Peer reviewed